First Turn Management LLC Raises Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

First Turn Management LLC grew its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 85.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 1,187,165 shares of the company's stock after purchasing an additional 546,776 shares during the period. Syndax Pharmaceuticals makes up about 3.6% of First Turn Management LLC's portfolio, making the stock its 7th biggest position. First Turn Management LLC owned about 1.40% of Syndax Pharmaceuticals worth $22,853,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Simplify Asset Management Inc. grew its holdings in shares of Syndax Pharmaceuticals by 62.5% during the 3rd quarter. Simplify Asset Management Inc. now owns 122,185 shares of the company's stock valued at $2,352,000 after purchasing an additional 46,992 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in shares of Syndax Pharmaceuticals by 54.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 428,949 shares of the company's stock valued at $8,806,000 after acquiring an additional 151,021 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Syndax Pharmaceuticals by 18.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 291,826 shares of the company's stock valued at $5,991,000 after acquiring an additional 46,463 shares in the last quarter. Renaissance Technologies LLC grew its position in Syndax Pharmaceuticals by 170.9% during the 2nd quarter. Renaissance Technologies LLC now owns 214,300 shares of the company's stock worth $4,400,000 after acquiring an additional 135,200 shares during the last quarter. Finally, Inspire Investing LLC increased its holdings in Syndax Pharmaceuticals by 23.2% in the 3rd quarter. Inspire Investing LLC now owns 21,308 shares of the company's stock worth $410,000 after purchasing an additional 4,018 shares in the last quarter.

Syndax Pharmaceuticals Stock Down 2.1 %

SNDX stock traded down $0.34 during midday trading on Tuesday, reaching $15.77. 1,488,735 shares of the company's stock traded hands, compared to its average volume of 1,150,461. The firm's fifty day moving average price is $18.82 and its 200-day moving average price is $20.15. Syndax Pharmaceuticals, Inc. has a 52 week low of $14.97 and a 52 week high of $25.34. The company has a market cap of $1.35 billion, a price-to-earnings ratio of -4.34 and a beta of 0.92.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last posted its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same quarter in the prior year, the business earned ($0.73) EPS. Analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.61 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Barclays upped their price target on shares of Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an "overweight" rating in a research report on Thursday, August 15th. Stifel Nicolaus raised their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. HC Wainwright upped their price target on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the company a "buy" rating in a research report on Monday. The Goldman Sachs Group increased their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. Finally, Citigroup lifted their target price on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday. Two equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $37.18.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).